drugset
drugset / Trial / NCT00642499

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499 ↗

Phase 2 Completed 103 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

Timeline

Start
2003-08
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 2.5 mg —
Subject Dronabinol Other / unclassified 40 mg —

Indications

HIV infectious disease